Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Dividend Updates
Outcome of Board Meeting - Final Dividend, Special Dividend, Annual General Meeting (AGM) Date & Book Closure Date as per enclosed file23-02-2021
23-02-2021
Sanofi India Ltd - 500674 - Audited Financial Results For The Year Ended 31St December 2020
We refer to our letter dated 8th February 2021 informing you of our Board Meeting that was scheduled today. The meeting of Board of Directors commenced at 2.30 p.m. and concluded at 5.40 p.m. The Board approved audited financial results for the year ended 31st December 2020. We enclose a copy of the auditor's report and audited financial results of the Company for the year ended 31st December 2020 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2020 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s Price Waterhouse & Co. Chartered Accountants LLP have issued the Audit Report with unmodified opinion for the financial year ended 31st December 2020.23-02-2021
Bristol-Myers, Sanofi to pay Hawaii $834 mn over Plavix warning label
Bristol-Myers and Sanofi, which produced Plavix in a partnership, in a joint statement vowed to appeal, saying the decision was "unsupported by the law and at odds with the evidence at trial"16-02-2021
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.15-02-2021
Sanofi's COVID-19 vaccine not ready in 2021, says CEO
In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data14-02-2021
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice of the Board Meeting of the Company published today, in newspapers, Business Standard and Sakal.09-02-2021
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.09-02-2021
Sanofi India Ltd - 500674 - Board to consider FY20 results & Final Dividend on February 23, 2021
Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 23, 2021, inter alia, to:1. Approve the audited accounts for the year ended December 31, 2020.2. Recommend final dividend for the period mentioned above.08-02-2021
Sanofi India Ltd - 500674 - Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 23Rd February 2021.
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2021 ,inter alia, to consider and approve Dear Sirs, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on 23rd February 2021; inter alia to: Approve the audited accounts for the year ended 31st December 2020. Recommend final dividend for the period mentioned above.08-02-2021
Sanofi India Ltd - 500674 - Proposed Divestment Of Soframycin(r) And Sofradex(r) Businesses
The Board of the Directors of Sanofi India Limited (the Company) at its meeting held today, reviewed the proposed plan of the Sanofi Group to globally sell some of its old brands along with their trademarks, which are owned by Sanofi Group. These include brands Soframycin(r) and Sofradex(r), which are manufactured (through a third-party manufacturing arrangement) and distributed by the Company. The Board also noted that upon completion of such sale by Sanofi Group, the Company will not have the authority to distribute products under these brands. The business of the Company under these brands was just 2.8% of the total sales of the Company for the nine months ended 30th September 2020. The Board approved a review of options, and assessment of how best to monetise value for these businesses in India. Please take the above information on record05-02-2021